Yunji (YJ) Q4 2024 earnings summary

Executive summary

• Focused on organic health as a core strategic objective, with significant operational and organizational enhancements in 2024 to drive future agility and growth.

• Completed consolidation of health and Yunji Select businesses, enabling better delivery of trusted healthy living solutions and strengthening the product trust chain.

• Q4 2024 revenues declined to RMB97.1 million (US$13.3 million), down from RMB149.1 million year-over-year, mainly due to soft consumer confidence and strategic product selection refinement.

• Fiscal year 2024 revenues were RMB417.7 million (US$57.2 million), down from RMB640.2 million in 2023.

• Cost structure optimized with significant reductions in fulfillment and technology expenses.

Financial highlights

• Q4 2024 net loss was RMB 85 million, compared to RMB 65.9 million in Q4 2023; adjusted net loss was RMB 84.5 million versus RMB 65 million.

• Fiscal year 2024 net loss was RMB123.1 million, improved from RMB165.1 million in 2023; adjusted net loss for fiscal year 2024 was RMB120.7 million, compared to RMB166.0 million in 2023.

• Total revenue for Q4 2024 was RMB 97.1 million, down from RMB149.1 million year-over-year.

• Gross margin for Q4 2024 was 48.3%, supported by strong customer loyalty to private labels.

• Cash and equivalents as of December 31, 2024, totaled RMB 219.4 million, down from RMB517.5 million at end-2023.

Outlook and guidance

• Plans to maintain financial discipline while investing strategically in high-potential categories to drive sustainable growth and improve profitability in 2025.

• Management aims to transform Yunji into an experiential health and wellness destination in 2025, expanding its health-focused ecosystem.

• Continued focus on optimizing product structure, shifting toward high-margin, high-repurchase products, and evolving into a service experience platform.